Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
50
Expected Date of Accrual
31 December 2026
Trial Chairperson
Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia
Trial Contact
qa@trog.com.au
Related Post
9 January, 2025
Tour de Cure grants support two valuable TROG trials
9 January 2025: Two important TROG Cancer Research trials
7 January, 2025
GenesisCare Foundation $300,000 donation to support TROG work
7 January 2025: TROG Cancer Research is advancing vital
